Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Staccato alprazolam for stereotypical prolonged seizures
2024-510950-29-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in epilepsy and status epilepticus (SE) comparing Staccato alprazolam with Placebo (2 arms). Primary endpoint: Treatment success for the treated seizure with no recurrence after 2 hours. Planned start Jul 2022; status: authorised.
02
Drugs
alprazolam
03
Conditions
epilepsystatus epilepticus (SE)
Beyond the preview
Go deeper on 2024-510950-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510950-29-00.